Search
Etelcalcetide
go.drugbank.com/drugs/DB12865ApprovedInvestigationalEtelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.
Categories: Sex Hormones and Insulins, Amino Acids, Peptides, and ProteinsProducts: Parsabiv 10mg solution for injection, Parsabiv 2.5mg solution for injectionGinseng
go.drugbank.com/drugs/DB01404ApprovedInvestigationalNutraceuticalGinseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties … Ginseng is also known to contain phytoestrogens.
Mixtures: Shine Oramin Natural Korean Ginseng + Royal Jelly with Multivitamins and Minerals.Categories: Herbs and Natural ProductsMinocycline
go.drugbank.com/drugs/DB01017ApprovedInvestigational[A190681] It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. … [A190723] Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.
Categories: Alimentary Tract and Metabolism, Antiinfectives and Antiseptics for Local Oral TreatmentProducts: Nu-minocycline, Enca 100mgCeftazidime
go.drugbank.com/drugs/DB00438ApprovedInvestigational[L32935] Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor [avibactam] to treat a variety of … Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding
Products: Ceftazidime and Dextrose, Ceptaz Inj 10gm/vialAmiodarone
go.drugbank.com/drugs/DB01118ApprovedInvestigationalBecause of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved for its approved indications, according to prescribing information.[L3561,L11265,L11286] … [A36817] Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation.
Synonyms: 2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuranCategories: Metabolic Side Effects of Drugs and SubstancesPrenylamine
go.drugbank.com/drugs/DB04825ApprovedWithdrawnPrenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.
Synonyms: N-(3,3-Diphenylpropyl)-alpha-methylphenaethylamin, N-(3,3-Diphenylpropyl)-alpha-methylphenethylamineCategories: Calcium-Regulating Hormones and AgentsPomalidomide
go.drugbank.com/drugs/DB08910ApprovedInvestigationalPomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Categories: Antineoplastic and Immunomodulating AgentsProducts: POMALYST CAPSULE 1MG, Pomalyst Capsules 1mgCephalexin
go.drugbank.com/drugs/DB00567ApprovedInvestigationalVet approved[A179071,A179074] This antibiotic contains a beta lactam and a dihydrothiazide. … [A179071] Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.[A179083,L6547] Cephalexin was approved by the FDA on 4 January 1971.
Products: Nu-cephalex Tab 250mg, Nu-cephalex Tab 500mgLemborexant
go.drugbank.com/drugs/DB11951ApprovedInvestigational[L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
Categories: Hypnotics and Sedatives, Sleep Initiation and Maintenance DisordersProducts: DAYVIGO FILM-COATED TABLET 10MG, Dayvigo 10mg Film coated tabletRanibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigational[A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO. … [L41399] In August 2022, other biosimilars CIMERLI, RAIVISIO, and RANOPTO were approved by the FDA, EC, and Health Canada respectively.[L42625,L43513,L49141]
Categories: Amino Acids, Peptides, and ProteinsProducts: LUCENTIS(10MG/ML), Lucentis 10mg/ml Solution for Injection